DUBLIN, Feb. 1, 2017 /PRNewswire/ -- Allergan plc
(NYSE: AGN), a leading global biopharmaceutical company, today
announced that it has successfully completed the acquisition of
LifeCell Corporation, a leading regenerative medicine company.
Allergan acquired LifeCell for approximately $2.9 billion in cash.
The Company plans to provide its 2017 guidance, including
LifeCell, as part of its fourth quarter and full year 2016 earnings
results on February 8, 2017.
"The completion of the LifeCell acquisition is an important
milestone for Allergan, serving as our entry point into
regenerative medicine as we continue to add to our world-class
aesthetic and plastic surgery business," said Brent Saunders, Chairman and CEO of
Allergan. "The combination of LifeCell's novel regenerative
medicine products coupled with Allergan's innovative medical
aesthetics and plastic surgery portfolio creates a more complete
product offering for plastic surgeons globally."
The acquisition adds LifeCell's novel, regenerative medicines
business, including its high-quality and durable portfolio of
dermal matrix products to Allergan's leading portfolio of medical
aesthetic products, breast implants and tissue expanders. Together,
these product lines create a world-class aesthetic and regenerative
medicine business providing significant opportunity to enhance the
overall product offering for plastic and general surgery
customers.
The LifeCell commercial portfolio features Acellular Dermal
Matrices, commonly used in breast reconstruction procedures and
complex hernia surgeries. Key products include
ALLODERM®, a human allograft tissue matrix used in
breast reconstruction post-masectomy; and REVOLVE™, a single use
high-volume fat grafting device used in plastic and
reconstructive procedures. Additionally, LifeCell markets
STRATTICE™, a porcine based tissue matrix used in complex abdominal
wall repair and for the surgical repair of damaged or ruptured soft
tissue. In addition to commercial products, Allergan has also
acquired LifeCell's innovative manufacturing capabilities and its
R&D operations, based in New
Jersey.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceuticals, devices
and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the
Company's R&D model, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. This approach has led to Allergan building one
of the broadest development pipelines in the pharmaceutical
industry with 70+ mid-to-late stage pipeline programs in
development.
Our Company's success is powered by our more than 16,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives everyday.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts, including with respect to
Allergan's acquisition of LifeCell are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting future clinical
results based on prior clinical results; the timing or outcome of
FDA approvals or actions, if any; successful integration of the
LifeCell acquisition and the ability to realize the anticipate
synergies and benefits of the LifeCell acquisition; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's and LifeCell's products;
difficulties or delays in manufacturing; the ability of Allergan to
complete the acquisition of LifeCell; and other risks and
uncertainties detailed in Allergan's periodic public filings with
the Securities and Exchange Commission, including but not limited
to Allergan's Annual Report on Form 10-K for the year ended
December 31, 2015 and Quarterly
Report on Form 10-Q for the quarter ended September 30, 2016 (certain of such periodic
public filings having been filed under the "Actavis plc" name).
CONTACTS:
|
Allergan:
|
|
Investors:
|
|
Lisa
DeFrancesco
|
|
(862)
261-7152
|
|
|
|
Media:
|
|
Mark
Marmur
|
|
(862)
261-7558
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-successfully-completes-lifecell-acquisition-300400110.html
SOURCE Allergan plc